Celldex Therapeutics' Topline Results From Its Phase 2 Trial Of Barzolvolimab For Moderate To Severe Chronic Spontaneous Urticaria Refractory To Antihistamines Met Primary Endpoint Showing Decrease In Disease Activity Across Multiple Doses
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics has announced positive topline results from its Phase 2 trial of Barzolvolimab for moderate to severe chronic spontaneous urticaria refractory to antihistamines. The trial met its primary endpoint, showing a decrease in disease activity across multiple doses.
November 06, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from the Phase 2 trial of Barzolvolimab could potentially boost Celldex Therapeutics' stock in the short term as it indicates progress in the company's drug development pipeline.
Positive clinical trial results often lead to an increase in a company's stock price as it indicates progress and potential future revenue. Given that the trial met its primary endpoint, this is likely to be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100